Baylor Genetics is a private company building in medical diagnostics / genetic testing, founded in 2015. Its shares do not trade on a public exchange.
Baylor Genetics has no published valuation.
Baylor Genetics specializes in clinically relevant genetic testing and helps determine an individual's chance of developing or passing on a genetic disorder, offering testing that can be used in deeply personal medical situations, including pregnancy and family planning, hereditary conditions. Its products include Baylor Genetics Whole Genome Sequencing, aimed at healthcare providers, researchers, and families.
As the sole sequencing core for the NIH Undiagnosed Diseases Network, Baylor Genetics uses rare disease data from uncharacterized conditions to provide deeper insight and more accurate diagnoses, work the company says has let it pioneer the history of genetic testing.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Baylor Genetics.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Baylor Genetics availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Baylor Genetics included.
No. Baylor Genetics is a private company; its shares do not trade on a public exchange.
The closest medical diagnostics / genetic testing peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
